SCHEMBL4310470

SCHEMBL4310470

O=C(OC(Cn1ncnn1)c1ccccc1Cl)N1CCC(Cc2ccc(F)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
FAAH O00519 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTR2B P41595 1/20 0.40
MAPK14 Q16539 1/20 0.40
CCR3 P51677 3/20 0.39
ATM Q13315 1/20 0.39
PKM P14618 1/20 0.38
CCR5 P51681 1/20 0.38
CYP3A4 P08684 2/20 0.38
GMNN O75496 1/20 0.38
TP53 P04637 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
THPO P40225 1/20 0.38
MTOR P42345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4309032 0.93 FAAH (0.41) MEN1KMT2AFAAHCYP2C9CYP2C19
SCHEMBL4306732 0.93 FAAH (0.47) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL13667455 0.93 FAAH (0.47) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL13667456 0.93 FAAH (0.47) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL4304784 0.91 FAAH (0.41) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL4307866 0.90 RIPK1 (0.39) FAAHCCR3
SCHEMBL4314273 0.90 SMN1; SMN2 (0.45) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL4308566 0.90 CCR3 (0.42) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL4304494 0.88 FAAH (0.39) MEN1KMT2APOLBFAAHCYP2C9
SCHEMBL4310209 0.87 HSD11B1 (0.48) POLBCYP2C9CYP2C19BLMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
EP-1879873-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK Holdings Co., Ltd. (KR) 2008-01-23 EP disclosed
US-20060258718-A1 Neurotherapeutic azole compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-11-16 US disclosed
WO-2006112685-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK HOLDINGS CO., LTD. (KR) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258718-A1 Neurotherapeutic azole compounds CHRNA10, CHRNA4, CHRNA3 MEN1 1549/4885KMT2A 1096/4885POLB 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.